Medicines
Discover all available medicines and treatments
Discover all available medicines and treatments
Brand: Sustiva, Stocrin
Efavirenz is a non-nucleoside reverse transcriptase inhibitor (NNRTI) used in combination with other antiretroviral agents for the treatment of HIV-1 infection. It works by binding to and inhibiting the reverse transcriptase enzyme, which HIV needs to replicate its genetic material. This prevents the virus from multiplying and can help to reduce the viral load in the body.
For the treatment of HIV-1 infection in combination with other antiretroviral agents.
Severe psychiatric symptoms, including suicidality, have been reported. Hepatic failure, sometimes fatal. Skin reactions including Stevens-Johnson syndrome. Efavirenz is contraindicated during pregnancy due to potential birth defects.
Outcome:
Reduced efavirenz levels
Mechanism:
Induction of CYP3A4
Outcome:
Increased efavirenz levels
Mechanism:
Inhibition of CYP2B6
Outcome:
Reduced efavirenz absorption
Mechanism:
Chelation
Most likely new formulation: Long-acting injectable (Year: 2026, 70% confidence)
Based on current usage trends and emerging resistance patterns, there is a 15% likelihood of revised dosing guidelines within the next 5 years.
Antiretroviral, Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI)
Benzoxazinone